Roche performs well in the first half of 2019, raising expectations

14 08 2019

· Group sales increase by 9% 1 at fixed exchange rates

Pharmaceutical sales up 10% with support from Ocrevus, Hemlibra, Tecentriq and Perjeta

· Diagnostics department sales increased by 2% due to growth in the Immunology department and strong overall growth in the second quarter

In the second quarter, Polivy received approval from the United States for the treatment of adults with chronic B-cell lymphoma and relapsed from those who received at least two prior treatments, and Rozlytrek was approved in Japan for the treatment of adult patients and children carrying neurotransmitters tyrosine kinase.

Dubai, UAE, August 7, 2019: Severn Schwan, Group President, commented on the Roche Group's results: "In the first half of the year, we achieved very good results, driven by strong demand for our new pharmaceuticals . These medications are important treatment options for cancer patients. Based on our positive performance in the first half, we are raising our expectations for the remainder of 2019. " Sales are expected to experience medium to high single-digit growth with fixed exchange rates. The focus on improving basic earnings per share is broadly in line with high selling rates at fixed exchange rates.

In the first half of 2019, sales grew 9% to CHF 30.5 billion and basic earnings per share were 13% higher than sales. Core operating income also increased 11% to reflect good business performance. Net income under International Financial Reporting Standards (IFRS) increased by 19% due to strong key results and the non-recurring impact of the revaluation of deferred tax positions and other items. disclosure of items related to the acquisition.

Pharmaceutical sales increased 10% to 24.2 billion Swiss francs. Ocrevus, used to treat multiple sclerosis, has been one of the main drivers of sales growth, along with hemophilia and the anti-cancer drugs Tecentriq, Perjeta and Avastin. Sales in Europe were affected (-4%) by competition from viable alternatives Herceptin (-45%) and MabThera / Rituxan (-36%). Sales in Japan increased 9%, driven by recently launched products including Hemlibra, Tecentriq and Perjeta. Global sales grew 17%, mainly due to strong sales of Herceptin, Avastin, MabThera / Rituxan as well as the launch of Alecensa and Perjeta.

Diagnostics sales increased by 2% to CHF 6.3 billion. Key solutions and Care Center played a key role in sales growth (+ 3%) driven by growth in the Immunology Diagnostics division. At the regional level, the Group achieved growth in Asia Pacific (+ 5%) and EMEA 2 (+ 3%). Sales in North America decreased (-2%).

Core operating income increased by 11%. In the pharmaceutical industry and 4% in the diagnostic department.

Major Achievements of Roche Medications

The US Food and Drug Administration has accelerated the approval of Polivy (polatuzumab vedotin-piiq) in combination with Bendamostine and Rituxan for the treatment of adults with chronic and relapsing B-cell lymphoma who have already received at least two treatments. The FDA's rapid approval program grants conditional approval to a drug that meets an unmet medical need for a critical illness. In Japan, the Ministry of Health, Labor and Welfare has authorized Japan to use the drug Rozlytrek (entrectinib) for the treatment of adult patients and children with neurotransmitter receptor tyrosine kinase (NTRK), solid tumors with advanced recurrence. Rozlytrek is the first anti-tumor drug in Japan to incorporate the NTRK gene, which has been identified in various hard-to-treat solid tumors, including the pancreas, thyroid, salivary glands, breast, colon, rectum and lungs.

Roche Diagnostics – Next Generation Solutions for Individual Treatments

Navify Tumor Board 2.0 is the first product manufactured in collaboration with GE Healthcare and put on the market. By combining the visualization and storage capabilities of medical images with other patient data, the product enables medical oncology groups with multidisciplinary teams developing cancer treatment plans – from To obtain a more complete view of each patient in the same place. The integration of GE Healthcare medical image viewer via Navify Tumor Board 2.0 allows radiologists to upload their patient records on the same control panel, where patient records and other specialties are stored in the cancer treatment team. Having complete diagnostic information in one place helps specialists use the limited time they have while medical oncology groups quickly review all relevant files and agree on the best treatment plan possible for each patient with cancer.

Roche has launched the Ventana HER2 Dual ISH Diagnostic Test with DNA Cocktail Probe for patients with eligible breast or stomach cancer for targeted therapy. HER2 – the human growth factor 2 receptor for human skin – is an important vital sign in breast and stomach cancer. Detection and inhibition can help manage these chronic diseases more effectively. This test is designed to be performed in one day, allowing physicians to achieve faster results than the most common methods of HER2 testing. The results can be read using a light transmission microscope, eliminating the need for a specialized fluorescence microscope. The cobas MTB-RIF / INH test for antibiotic resistance in the DNA of tuberculosis has been launched in countries that accept CE marking. This test is part of a list of fungal tests including MTB and MAI cobas tests for use in 6800 / 8800cobas systems. This step leads to the continued expansion of the 6800/8800 cobas tests, which consolidates results and improves efficiency.

-End-

About Roche

The Roche Group is a global leader in the pharmaceutical industry and diagnostic innovations focused on the development of medical science to improve people's lives. The unique approach that combines pharmaceutical drugs with Roche's diagnostic tools has led to a leadership position in personal health care, a strategy to provide the best possible treatment to every patient.

Roche, the world's largest biotech company, provides unique medicines for oncology, immunology, infectious diseases, ophthalmology and central nervous system diseases. Roche is a world leader in laboratory diagnostics and tissue cancer, as well as a leader in diabetes management.

Founded in 1986, Roche continues to research the best ways to prevent, diagnose and treat diseases and make a positive contribution to society, to enable patients to have easy access to medical innovations in life. working with all stakeholders. Thirty Roche drugs have been included in the WHO Model Lists of Essential Medicines, including life-saving antibiotics, antimalarials, and anti-cancer drugs. Roche has also been named by the Dow Jones Sustainability Indexes (DJSI), the leading sustainability group in the pharmaceutical, biotechnology and life sciences industries for nine consecutive years.

Headquartered in Basel, Switzerland, the Roche Group is present in more than 100 countries and has 94,000 employees worldwide in 2017. In the same year, the Group invested 10.4 billion Swiss francs in research and development for a turnover of 53.3 billion Swiss francs. In the United States, Genetech is a subsidiary of Roche and is wholly owned by the group. Roche is also the largest shareholder of Shogai Pharmaceutical in Japan.

For more information, visit www.roche.com.

All trademarks used or mentioned in this news are protected by law.

1 Unless otherwise indicated, all growth rates in this document are at fixed exchange rates (2018 average fixed exchange rates)

2 EMEA = Europe, Middle East and Africa

© Press Release 2019